http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008057505-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_19102c6e52094451d43b8ad6fbd8e386 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8b4ee13af463c18c765406625e1c5d44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bd8084fb229c6d865cc5edbb89634eb2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28 |
| filingDate | 2007-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d6689a9aa700221282ece94c5c0e352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a687f87500abb555d96e98e55f7fae7 |
| publicationDate | 2008-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2008057505-A2 |
| titleOfInvention | Suppressive macrophages, c-reactive protein and the treatment of systemic lupus erythematosus and immune thrombocytopenic purpura |
| abstract | The present invention relates to the use of suppressive macrophage or dendritic cells (activated with C-reactive protein or CRP-related compounds), for the treatment of various disease states and conditions associated with immune thrombocytopenic purpura (ITP) and/or systemic lupus erythematosus (SLE), including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects, including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein. In another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition associated with systemic lupus erythematosus or ITP will have an outbreak is an additional aspect of the present invention. In the case of ITP, methods of the present invention are used to increase platelet counts in the treated patient. In addition, in the case of ITP, the present invention relates to the use of CRP or a CRP-related compound in the absence of suppressive macrophages for the treatment of ITP. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009148566-A3 |
| priorityDate | 2006-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 354.